GB9816781D0 - Herpes virus vectors for dendritic cells - Google Patents

Herpes virus vectors for dendritic cells

Info

Publication number
GB9816781D0
GB9816781D0 GBGB9816781.0A GB9816781A GB9816781D0 GB 9816781 D0 GB9816781 D0 GB 9816781D0 GB 9816781 A GB9816781 A GB 9816781A GB 9816781 D0 GB9816781 D0 GB 9816781D0
Authority
GB
United Kingdom
Prior art keywords
herpes virus
dendritic cells
virus vectors
cell
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9816781.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Priority to GBGB9816781.0A priority Critical patent/GB9816781D0/en
Publication of GB9816781D0 publication Critical patent/GB9816781D0/en
Priority to KR1020017001361A priority patent/KR100635246B1/ko
Priority to DK99936848T priority patent/DK1100942T3/da
Priority to AU51822/99A priority patent/AU765105B2/en
Priority to ES99936848T priority patent/ES2294848T3/es
Priority to EP99936848A priority patent/EP1100942B1/en
Priority to BR9912653-2A priority patent/BR9912653A/pt
Priority to PT99936848T priority patent/PT1100942E/pt
Priority to AT99936848T priority patent/ATE374829T1/de
Priority to GB0104400A priority patent/GB2361921B/en
Priority to HK01108180.2A priority patent/HK1037925B/xx
Priority to IL14112699A priority patent/IL141126A0/xx
Priority to DE69937239T priority patent/DE69937239T2/de
Priority to CA002337494A priority patent/CA2337494C/en
Priority to US09/744,942 priority patent/US6641817B1/en
Priority to JP2000563814A priority patent/JP4430824B2/ja
Priority to CN99811376XA priority patent/CN1384884B/zh
Priority to PCT/GB1999/002529 priority patent/WO2000008191A2/en
Priority to US09/833,073 priority patent/US6713067B2/en
Priority to US10/766,897 priority patent/US7118755B2/en
Priority to US11/155,688 priority patent/US20050249707A1/en
Priority to US11/333,309 priority patent/US7811582B2/en
Priority to CY20071101634T priority patent/CY1107844T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB9816781.0A 1998-07-31 1998-07-31 Herpes virus vectors for dendritic cells Ceased GB9816781D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB9816781.0A GB9816781D0 (en) 1998-07-31 1998-07-31 Herpes virus vectors for dendritic cells
PCT/GB1999/002529 WO2000008191A2 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells
HK01108180.2A HK1037925B (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells
DE69937239T DE69937239T2 (de) 1998-07-31 1999-08-02 Herpesvirusvektoren für dendritische zellen
AU51822/99A AU765105B2 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells
ES99936848T ES2294848T3 (es) 1998-07-31 1999-08-02 Vectores de virtus del herpes para celulas dendriticas.
EP99936848A EP1100942B1 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells
BR9912653-2A BR9912653A (pt) 1998-07-31 1999-08-02 Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
PT99936848T PT1100942E (pt) 1998-07-31 1999-08-02 Vectores virais do tipo herpes para células dendríticas
AT99936848T ATE374829T1 (de) 1998-07-31 1999-08-02 Herpesvirusvektoren für dendritische zellen
GB0104400A GB2361921B (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells
KR1020017001361A KR100635246B1 (ko) 1998-07-31 1999-08-02 수상세포를 숙주로 하는 허피스 바이러스 벡터
IL14112699A IL141126A0 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells
DK99936848T DK1100942T3 (da) 1998-07-31 1999-08-02 Herpesvirusvektorer til dendristiske celler
CA002337494A CA2337494C (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells
US09/744,942 US6641817B1 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells
JP2000563814A JP4430824B2 (ja) 1998-07-31 1999-08-02 樹状細胞のためのヘルペスウイルスベクター
CN99811376XA CN1384884B (zh) 1998-07-31 1999-08-02 用于树突细胞的疱疹病毒载体
US09/833,073 US6713067B2 (en) 1998-07-31 2001-04-12 Herpes viruses for immune modulation
US10/766,897 US7118755B2 (en) 1998-07-31 2004-01-30 Herpes viruses for immune modulation
US11/155,688 US20050249707A1 (en) 1998-07-31 2005-06-20 Herpes virus vectors for dendritic cells
US11/333,309 US7811582B2 (en) 1998-07-31 2006-01-18 Herpes viruses for immune modulation
CY20071101634T CY1107844T1 (el) 1998-07-31 2007-12-27 Φορεις ερπητοϊου για δενδριτικα κυτταρα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9816781.0A GB9816781D0 (en) 1998-07-31 1998-07-31 Herpes virus vectors for dendritic cells

Publications (1)

Publication Number Publication Date
GB9816781D0 true GB9816781D0 (en) 1998-09-30

Family

ID=10836553

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9816781.0A Ceased GB9816781D0 (en) 1998-07-31 1998-07-31 Herpes virus vectors for dendritic cells
GB0104400A Expired - Lifetime GB2361921B (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0104400A Expired - Lifetime GB2361921B (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells

Country Status (17)

Country Link
US (2) US6641817B1 (cg-RX-API-DMAC7.html)
EP (1) EP1100942B1 (cg-RX-API-DMAC7.html)
JP (1) JP4430824B2 (cg-RX-API-DMAC7.html)
KR (1) KR100635246B1 (cg-RX-API-DMAC7.html)
CN (1) CN1384884B (cg-RX-API-DMAC7.html)
AT (1) ATE374829T1 (cg-RX-API-DMAC7.html)
AU (1) AU765105B2 (cg-RX-API-DMAC7.html)
BR (1) BR9912653A (cg-RX-API-DMAC7.html)
CA (1) CA2337494C (cg-RX-API-DMAC7.html)
CY (1) CY1107844T1 (cg-RX-API-DMAC7.html)
DE (1) DE69937239T2 (cg-RX-API-DMAC7.html)
DK (1) DK1100942T3 (cg-RX-API-DMAC7.html)
ES (1) ES2294848T3 (cg-RX-API-DMAC7.html)
GB (2) GB9816781D0 (cg-RX-API-DMAC7.html)
IL (1) IL141126A0 (cg-RX-API-DMAC7.html)
PT (1) PT1100942E (cg-RX-API-DMAC7.html)
WO (1) WO2000008191A2 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
GB0009079D0 (en) * 2000-04-12 2000-05-31 Neurovex Ltd Herpes viruses for immune modulation
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
JP4810042B2 (ja) * 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
WO2002087625A1 (en) * 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
EP2140879A1 (en) * 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
US8216564B2 (en) 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Hsvを用いた抗腫瘍剤
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US20100008944A1 (en) * 2005-07-29 2010-01-14 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
KR100878017B1 (ko) * 2007-04-09 2009-01-14 인제대학교 산학협력단 이종 유전자 발현을 위한 숙주균 및 그의 이용방법
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010105311A1 (en) 2009-03-20 2010-09-23 Angioblast Systems, Inc. Production of reprogrammed pluripotent cells
AU2011207348A1 (en) 2010-01-21 2012-08-02 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
EP3134546A4 (en) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
HK1248812A1 (zh) 2015-03-06 2018-10-19 Dana-Farber Cancer Institute, Inc. 预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3368157B1 (en) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
JP2019512271A (ja) 2016-03-21 2019-05-16 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド T細胞疲弊状態特異的遺伝子発現調節因子およびその使用
CA3034643A1 (en) 2016-09-20 2018-03-29 Ellen Weisberg Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
WO2018226685A2 (en) 2017-06-06 2018-12-13 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
EP3759125A4 (en) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. METHOD OF CANCER TREATMENT USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNCHECKPOINT BLOCKING REAGENTS
JP7245260B2 (ja) * 2018-03-19 2023-03-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ehv挿入部位ul43
MX2020010094A (es) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
WO2021150925A1 (en) 2020-01-24 2021-07-29 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
EP4343004A3 (en) 2020-10-19 2024-09-11 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
CA3249166A1 (en) 2022-02-16 2023-08-24 The Johns Hopkins University METHODS FOR REDUCING PATHOLOGICAL ALPHA-SYNUCLEIN USING AGENTS THAT MODULATE FNDC5 OR BIOLOGICALLY ACTIVE FRAGMENTS THEREIN
WO2025034542A1 (en) 2023-08-04 2025-02-13 Cornell University Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003207A1 (en) * 1992-07-31 1994-02-17 President And Fellows Of Harvard College Herpesvirus vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
US7063851B2 (en) * 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation

Also Published As

Publication number Publication date
EP1100942B1 (en) 2007-10-03
WO2000008191A2 (en) 2000-02-17
CY1107844T1 (el) 2013-06-19
CN1384884A (zh) 2002-12-11
GB2361921A (en) 2001-11-07
BR9912653A (pt) 2001-05-02
PT1100942E (pt) 2007-12-06
IL141126A0 (en) 2002-02-10
KR100635246B1 (ko) 2006-10-19
JP4430824B2 (ja) 2010-03-10
WO2000008191A3 (en) 2000-06-08
AU5182299A (en) 2000-02-28
DK1100942T3 (da) 2008-02-04
CA2337494A1 (en) 2000-02-17
ATE374829T1 (de) 2007-10-15
AU765105B2 (en) 2003-09-11
CA2337494C (en) 2009-06-23
EP1100942A2 (en) 2001-05-23
KR20010072162A (ko) 2001-07-31
ES2294848T3 (es) 2008-04-01
DE69937239T2 (de) 2008-07-24
HK1037925A1 (en) 2002-02-22
US20050249707A1 (en) 2005-11-10
US6641817B1 (en) 2003-11-04
CN1384884B (zh) 2010-12-08
DE69937239D1 (de) 2007-11-15
GB0104400D0 (en) 2001-04-11
GB2361921B (en) 2003-12-17
JP2003502008A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
GB2361921B (en) Herpes virus vectors for dendritic cells
ATE224442T1 (de) Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
PT1573465E (pt) Método e sistema para detecção heurística de infecções por vírus no código executável
HU9502949D0 (en) Polipeptides, polinucleotides, vectors and host cells, and vaccines against hepatitis virus infection, diagnostics, immunoassay and culturing methods
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
EP1192948A3 (en) Use of HSV mutant in the treatment of cancer
TR199900656T2 (xx) �ndanonlar ile 262 ve 20S proteazomun engellenmesi.
AU1632392A (en) Recombinant avipox virus, the culture of cells infected with this virus and vaccines for poultry derived from this virus
IL102915A0 (en) Soluble low density lipoprotein receptor and its preparation
GB2376687A (en) Herpes viruses for immune modulation
ATE234628T1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
OA09653A (en) Rubella peptides
GR3015437T3 (en) Non-a non-b sequences.
AU6943994A (en) Hepatitis c virus cell propagation and related methods
黄念宁 et al. 1-Soliton of the 1D magnetic system with an easy plane
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
Jeong et al. Site symmetry of Er sup 3 sup+ in In sub 0 sub. sub 5 Ga sub 0 sub. sub 5 P
Burgos Jr We Forum, vol xviii No. 51-Apr. 17-23, 1995
周文豪 CALLS OF THE EMERALD TREEFROG, RHACOPHORUS SMA RAGDINUS, IN TAIWAN
Ranieri US Private Investment In 1990
MX9709514A (es) Viruses de fowlpox recombinantes y usos de los mismos.
Burgos Jr We Forum, vol xix No. 50-Apr. 8-14, 1996
胡冠章 GROUP THEORY METHODFOR ENUMERATION OFOUTERPLANAR GRAPHS
UA40123A (uk) Спосіб отримання препарату опроміненої крові

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application
AT Applications terminated before publication under section 16(1)